53963-43-2

Basic information

• Product Name: GINSENOSIDEF1
• Synonyms: (20S)-20-(β-D-Glucopyranosyloxy)dammar-24-ene-3β,6α,12β-triol;3β,6α,12β-Trihydroxy-5α-dammar-24-en-20-yl β-D-glucopyranoside;(3b,6a,12b)-3,6,12-Trihydroxydammar-24-ene-20-yl beta-D-glucopyranoside;Ginsenoside F1;GINSENOSIDE F1(P);20(S)-Ginsenoside F1(3b,6a,12b)-3,6,12-Trihydroxydammar-24-ene-20-yl beta-D-glucopyranoside;20(S)-Ginsenoside F1;Panaxoside Aprogenin
• CAS NO: 53963-43-2
• Molecular Formula: C₃₆H₆₂O₉
• Molecular Weight: 638.87
• Product Categories: chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract
• Mol File: 53963-43-2.mol

Chemical Properties

• Boiling Point: 752.9°Cat760mmHg
• Flash Point: 409.1°C
• Appearance: /
• Density: 1.23g/cm³
• Vapor Pressure: 3.65E-26mmHg at 25°C
• Refractive Index: 1.58
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly )
• PKA: 12.94±0.70(Predicted)
• CAS DataBase Reference: GINSENOSIDEF1(CAS DataBase Reference)
• NIST Chemistry Reference: GINSENOSIDEF1(53963-43-2)
• EPA Substance Registry System: GINSENOSIDEF1(53963-43-2)

Safety Data

• Hazardous Substances Data: 53963-43-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
GINSENOSIDEF1 is used as an active pharmaceutical ingredient for its anti-cancer therapeutic properties. It has the ability to inhibit human cytochrome P450 enzymes, which are involved in the metabolism of various drugs and toxins. This inhibition can potentially enhance the effectiveness of certain cancer treatments and reduce the risk of drug interactions.
Used in Liver Protection:
GINSENOSIDEF1 is also used as a hepatoprotective agent, providing protective effects on the liver. This is particularly important in the context of cancer treatment, as many chemotherapy drugs can cause liver damage. By offering liver protection, GINSENOSIDEF1 may help to mitigate some of the side effects associated with cancer treatment.

InChI:InChI=1/C36H62O9/c1-19(2)10-9-12-36(8,45-31-28(43)27(42)26(41)24(18-37)44-31)35(7)15-14-34(6)21-16-22(38)29-32(3,4)25(40)11-13-33(29,5)20(21)17-23(39)30(34)35/h10,20-31,37-43H,9,11-18H2,1-8H3/t20?,21?,22-,23+,24-,25?,26-,27-,28-,29?,30-,31+,33-,34-,35+,36-/m1/s1

Upstream product

• 22427-39-0 ginsenoside-Rg₁ 
• 52286-59-6 ginsenoside Re 

Relevant articles and documents

Characterization of metabolism and in vitro permeability study of notoginsenoside R1 from radix notoginseng

As a main and characteristic constituent in Radix notoginseng, the fate of notoginsenoside R1 (NGR1) in human is largely unknown. The present study investigated, for the first time, NGR1 metabolism by human intestinal bacteria and liver subcellular fractions, and permeability properties of NGR1 and resultant metabolites on a Caco-2 model. Samples were qualitatively analyzed using HPLC-MS/MS and quantitatively determined using HPLC-UV. When incubated with pooled human intestinal bacteria anaerobically, NGR1 showed biphasic elimination: an insignificant decrease in the first 8 h followed by a rapid elimination during 8-48 h. Four metabolites, three unambiguously identified as ginsenosides Rg1, F1 and 20(S)-protopanaxatriol formed via stepwise deglycosylation, and one tentatively assigned as a dehydrogenated protopanaxatriol with transformation occurring at the tetracyclic triterpenoid skeleton, were produced sequentially. Rg1 and F1 were formed transiently at low apparent velocities, while 20(S)-protopanaxatriol was the major metabolite with a formation rate close to the rate of NGR1 elimination and a low elimination rate. NGR1 remained intact in human liver S9 or microsomes over 1 h. Transport study of NGR1 and its metabolites revealed an ascending permeability order with stepwise deglycosylation. Taken together, the results revealed a determinant role of intestinal bacteria in the overall disposition and potential bioactivity of NGR1 in human.

Enzymatic preparation of ginsenosides Rg2, Rh1, and F1 from protopanaxatriol-type ginseng saponin mixture

During investigations on the hydrolysis of a protopanaxatriol-type saponin mixture by various glycoside hydrolases, it was found that two minor saponins, ginsenosides Rg2 and Rh1, were formed in high yields by crude β-galactosidase from Aspergillus oryzae and crude lactase from Penicillium sp., respectively. Moreover, a crude preparation of naringinase from Penicillium decumbens readily hydrolyzed a protopanaxatriol-type saponin mixture to give an intestinal bacterial metabolite, ginsenoside F1 as the main product. A crude preparation of hesperidinase from Penicillium sp. selectively hydrolyzed ginsenoside Re into ginsenoside Rg1. This is the first report on the enzymatic preparation of minor saponins, ginsenosides Rg2 and Rh1, and of an intestinal bacterial metabolite, ginsenoside F1, with a high efficiency from a protopanaxatriol-type saponin mixture.